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PI3K mediated activation of GSK-3β 
reduces at-level primary afferent growth 
responses associated with excitotoxic spinal 
cord injury dysesthesias
Sonja K Bareiss1*, Elizabeth Dugan1 and Kori L Brewer2
Abstract 
Background: Neuropathic pain and sensory abnormalities are a debilitating secondary consequence of spinal cord 
injury (SCI). Maladaptive structural plasticity is gaining recognition for its role in contributing to the development of 
post SCI pain syndromes. We previously demonstrated that excitotoxic induced SCI dysesthesias are associated with 
enhanced dorsal root ganglia (DRG) neuronal outgrowth. Although glycogen synthase kinase-3β (GSK-3β) is a known 
intracellular regulator neuronal growth, the potential contribution to primary afferent growth responses following SCI 
are undefined. We hypothesized that SCI triggers inhibition of GSK-3β signaling resulting in enhanced DRG growth 
responses, and that PI3K mediated activation of GSK-3β can prevent this growth and the development of at-level pain 
syndromes.
Results: Excitotoxic SCI using intraspinal quisqualic acid (QUIS) resulted in inhibition of GSK-3β in the superficial 
spinal cord dorsal horn and adjacent DRG. Double immunofluorescent staining showed that GSK-3βP was expressed 
in DRG neurons, especially small nociceptive, CGRP and IB4-positive neurons. Intrathecal administration of a potent 
PI3-kinase inhibitor (LY294002), a known GSK-3β activator, significantly decreased GSK-3βP expression levels in the 
dorsal horn. QUIS injection resulted in early (3 days) and sustained (14 days) DRG neurite outgrowth of small and sub-
sequently large fibers that was reduced with short term (3 days) administration of LY294002. Furthermore, LY294002 
treatment initiated on the date of injury, prevented the development of overgrooming, a spontaneous at-level pain 
related dysesthesia.
Conclusions: QUIS induced SCI resulted in inhibition of GSK-3β in primary afferents and enhanced at-level DRG 
intrinsic growth (neurite elongation and initiation). Early PI3K mediated activation of GSK-3β attenuated QUIS-induced 
DRG neurite outgrowth and prevented the development of at-level dysesthesias.
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Background
Chronic neuropathic pain and sensory abnormalities 
are common secondary consequences of spinal cord 
injury (SCI), affecting >60% of patients with traumatic or 
ischemic injury [1–4], and effective treatments for this 
pain remain elusive. Clinically, SCI pain and associated 
dysesthesias manifest as at- and below-level neuropathic 
symptoms that are defined as either spontaneous (pain 
independent of peripheral stimuli) or evoked (occur-
ring in responses to a noxious or non-noxious stimuli) 
[1, 3]. At-level pain is characterized by a dermatomal 
band of hypersensitivity within two segments adjacent 
to the site of injury [1, 5]. Most investigations into the 
development of at-level pain have focused on the spinal 
(lesion epicenter) and supraspinal mechanisms. However, 
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recent evidence shows that injury to the cord results 
in enhanced intrinsic growth and hyperexcitability of 
adjacent peripheral afferents that may contribute to the 
development of at-level pain syndromes [6–9]. Further-
more, we recently demonstrated that quisqualic acid 
(QUIS) induced SCI results in DRG growth responses 
that are enhanced in animals that develop at-level dys-
esthesias, suggestive of a role in maladaptive peripheral 
growth in the development of post-spinal injury pain [6]. 
Peripheral nervous system contributions to SCI pain are 
supported by the finding that injury to the cord induces 
sprouting of primary afferent projections that may con-
tribute to enhanced dorsal horn synaptogenesis and noci-
ceptive signal amplification [10–15]. Despite the growing 
evidence to support maladaptive peripheral afferent 
structural plasticity in the development of at-level spi-
nal injury pain, the intracellular signaling mechanisms 
that mediate these morphological effects are largely 
undefined.
A potential target mechanism impacting neuronal 
growth responses in post spinal injury pain involves 
the intracellular signaling molecule, glycogen syn-
thase kinase-3β (GSK-3β). GSK-3β is highly expressed 
in the nervous system, and is particularly abundant in 
neurons where it plays a critical role in regulating neu-
ronal growth, gene expression, and cell survival [16, 17]. 
Although GSK-3β exerts a diverse array of cellular func-
tions, there is ample evidence for the influence of GSK-3β 
on neuronal plasticity through its regulation of structural 
proteins [18–22]. GSK-3β is serine/threonine kinase that 
under resting conditions is considered constitutively 
active, and is inactivated by phosphorylation of the Ser-9 
residue. When active, GSK-3β causes growth cone col-
lapse and suppresses axonal growth [20, 23, 24]. Extra-
cellular growth promoting cues, such as neurotrophins 
and Wnts, signal to phosphorylate/inactivate GSK-3β, 
causing axon elongation [16, 20, 25–27]. Inactivation of 
GSK-3β allows the dephosphorylated GSK-3β substrates 
to bind cytoskeletal proteins to directly promote neurite 
outgrowth [20, 27–33]. In support of GSK-3β as a media-
tor of aberrant sensory growth and pain, GSK-3β is a 
convergent downstream signaling effector of established 
pro-nociceptive signals factors released following nerv-
ous system injury including nerve growth factor (NGF) 
and Wnts [34–39]. Injury induced upregulation of these 
chemical signals leads to activation of phosphatidylino-
sitol 3-kinase (PI3K) and the subsequent inhibition of 
GSK-3β that may positively promote axonal elonga-
tion that contribute to the development of SCI pain [20, 
40–42]. Although studies support a role for PI3K in the 
development of neuropathic and nociceptive pain follow-
ing injury through neurochemical plasticity/central sen-
sitization [36, 43–46], the role of PI3K-GSK3β signaling 
in modulating aberrant sensory growth and the develop-
ment of spinal injury induced pain is unclear.
In this study, we investigated PI3K-GSK-3β signaling as 
a potential mechanism by which spinal injury promotes 
intrinsic growth of primary afferents that contributes to 
the development of at-level dysesthesias. Using the QUIS 
model of excitotoxic SCI, we demonstrated that injury to 
the dorsal gray matter was associated with GSK-3β inhi-
bition and DRG growth responses associated with at-
level dysesthesias. Further, PI3K mediated activation of 
GSK-3β reduced primary afferent growth responses and 
prevented the development of at-level dysesthesias.
Results
GSK‑3β is inhibited in spinal dorsal horn and DRG 
following QUIS induced SCI
GSK-3β is constitutively active under resting condi-
tions, with phosphorylation at Ser-9 residue resulting in 
GSK-3β inhibition and neurite elongation [19, 20, 47]. 
Our previous report demonstrated that QUIS-induced 
SCI resulted in enhanced DRG neurite outgrowth at 
14  days post-injury [6]. To investigate the relationship 
of GSK-3β activity following QUIS induced injury we 
used a phosphor-Ser9-GSK-3β (GSK-3βP) antibody as a 
marker of inhibition and performed immunohistochem-
istry on spinal cord cross sections and DRG just caudal 
(L1) and ipsilateral to the site of injection 14  days after 
QUIS-injury or sham operation. Due to changes in lami-
nae structures following QUIS injection, the L1 level was 
used for analysis. QUIS-injection (n = 6) resulted in sig-
nificant increases in GSK-3βP expression in the superfi-
cial dorsal horn and DRG compared to saline controls 
(n  =  5) (Figure  1a), showing significant increases in 
thickness and intensity in GSK-3βP expression that were 
uniformly distributed from the medial and lateral dorsal 
horn. Quantitative analysis showed that GSK-3βP expres-
sion was significantly increased following QUIS-injection 
compared to sham injected-animals (p < 0.05). Western 
blot analysis of spinal cord and DRG (T12, the spinal 
injection level) 14  days following surgery, showed sig-
nificant increases in ratios of GSK-3βP over total GSK-3β 
in QUIS (n = 3) compared to sham-injected (n = 3) ani-
mals, providing further support of these biochemical 
changes following spinal injury (Figure 1d, e).
To determine the cell types that associated with 
GSK-3βP expression following QUIS-injection, we 
double immunofluorescently labelled using phosphor-
Ser9-GSK-3β with nociceptive markers (IB4, non-pep-
tidertic; CGRP, peptidertic), and Aβ-fibers (NF200) 
(Figure  2). GSK-3βP co-localized with IB4, CGRP 
and NF200, however expression was greatest with 
small nociceptive proteins. Together, these data sup-
port QUIS injection results in inhibition of GSK-3β in 
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Figure 1 QUIS-injection increased GSK-3βP in the spinal cord dorsal horn and DRG ipsilateral at and just caudal to the level of injury compared to 
saline-injected (sham) 14 days following injury. a Representative immunofluorescence image of GSK-3βP in the superficial dorsal horn (L1) and DRG 
(L1, ipsilateral site of injection) shows increased GSK-3β phosphorylation (inhibition) following QUIS-injection compared to sham operated controls 
(Sham, n = 5, QUIS n = 6). b, c Bar graphs represent mean densitometric values of GSK-3βP in spinal cord (b) and DRG (c). d, e Western blot analysis 
of the SC and DRG taken from the level of the lesion shows that GSK-3βP expression was significantly increased 14 days following QUIS-injection 
(Sham, n = 3 and QUIS, n = 3). Error bars ± SEM (*p < 0.05). Scale bars spinal cord 100 μm, DRG 50 μm.
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primary afferents (DRG and spinal cord afferent termi-
nals) 14 days after injury.
Intrathecal delivery of a PI3K inhibitor, LY294002, activates 
spinal GSK‑3β and decreases QUIS spinal cord injury 
induced DRG growth responses
We and others have recently reported that injury to the 
cord results in enhanced DRG growth responses, show-
ing that SCI growth promoting effects are evident at 
early (3 days) and later stage (14 days) post injury [6, 8]. 
Since GSK-3β inhibition has an established role in neu-
rite outgrowth [20, 22, 39], we asked if alterations in 
GSK-3β were evident early (3  days), and if application 
of a GSK-3β activator could reverse these spinal injury 
induced changes. For these experiments, rats were ran-
domly assigned into three groups: sham vehicle (sham 
veh; 10% DMSO, n  =  5) control, QUIS-vehicle (QUIS 
veh; 10% DMSO, n =  5), or QUIS LY294002 (QUIS LY, 
2.5  μg/10  μL, n  =  4), in each group animals received 
the same volume of infusions [36]. LY294002, a PI3K 
inhibitor and known activator of GSK-3β, was intrathe-
cally delivered once daily for 3 consecutive days start-
ing on the day of surgery. Three days following surgery, 
immunofluorescence staining was performed on DRG 
and spinal cord cross sections (from the level of L1-2, 
just caudal the lesion). Similar to later stage time point 
(14  days) sham vehicle treated animals showed low lev-
els of GSK-3βP expression (Figure 1), while QUIS-injury 
induced a significant increase in the ipsilateral spinal dor-
sal horn (p < 0.05) (Figure 3a–c). QUIS-injured animals 
treated with LY294002 showed a marked decrease in 
GSK-3βP immunofluorescence in the spinal dorsal horn 
(p < 0.05) (Figure 3a–c). A similar response was observed 
in the DRG, however these results were not statistically 
Figure 2 Double immuno-labeling with GSK-3βP and nociceptive markers (IB4 and CGRP), and mechanoreceptive marker (NF200) from the level 
of QUIS-injection 14 days following SCI. Merged images demonstrate co-localization of nociceptive markers (afferent c-fibers) or mechanoreceptive 
markers (myelinated A-fibers) with GSK-3βP. Yellow regions indicate protein co-localization. GSK-3βP was highly expressed in small-diameter, nocic-
eptive neurons (arrowheads) and less frequent in large, mechanoreceptive fibers. Scale bar indicates 25 μm.
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significant (Figure  3a, c). Together, the results suggest 
that QUIS injection results in early (3 days) and extended 
(14 days) alterations in GSK-3β activity.
To determine if DRG neuronal growth paralleled the 
alterations in GSK-3β following QUIS injury, we assessed 
DRG growth responses three days following surgery and 
the effects of intrathecal drug LY294002 delivery. We 
found that QUIS-injection resulted in robust increases 
in the neurons with neurites (42%, n  =  neurons with 
neurites/neurons, 278/655, p  <  0.01) and neurite elon-
gation (160.7 μm ± 15.5, n = 278, p < 0.001) compared 
to sham-vehicle treated controls (35%, n  =  243/696; 
90.4  μm  ±  13.0, n  =  243) (Figure  4a–c). LY294002 
delivered immediately following QUIS-injection and 
daily for the 3 days survival period, significantly reduced 
the injury induced DRG outgrowth (17%, n = 255/1,500; 
70.2  μm  ±  10.4, n  =  255, p  <  0.001) (Figure  4a–c). 
Although injury induced neurite elongation was evident 
in small, medium, and large neurons, only small neurons 
from QUIS-injected animals showed statistically signifi-
cant increases compared to sham vehicle treated controls 
(97.2 μm ± 16.8, n = 79, p < 0.05) (Figure 4d). LY294002 
attenuated these injury induced growth responses 
in small (19%, 51.5  μm  ±  7.6, p  <  0.01, n  =  133) and 
medium (20%, 69.8 μm ±  14.2, p  <  0.05, n =  68) neu-
rons (Figure 4d). These data suggest that QUIS-injection 
Figure 3 GSK-3β is inhibited in the spinal dorsal horn and DRG 3 day following QUIS injection. Immunofluorescent staining of GSK-3βP in the spinal 
cord dorsal horn (top row) and DRG (bottom row) is increased 3 days following QUIS-induced SCI compared to sham vehicle treated controls; 3 days 
of LY294002 (LY) treatment significantly reduces GSK-3βP staining following QUIS-induced SCI. Quantification of GSK-3βP immunofluorescence 
intensity in SC (a) and DRG (b) (mean ± SEM. *p < 0.05. Scale bar 50 μm). Number of animals per group: sham vehicle (veh) n = 5, QUIS (veh) n = 5, 
QUIS (LY) n = 4.
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Figure 4 Intrathecal delivery of a GSK-3β activator (LY294002, LY; selective PI3K inhibitor) reduces DRG neurite outgrowth 3 days after QUIS-
induced SCI. a QUIS-injection (QUIS veh) resulted in robust neurite outgrowth 3 days after injury compared to sham veh treated. Animals that 
received LY94002 following injury (QUIS LY) show growth responses similar to controls (sham veh). b Quantification of % of neurons with neurites. 
c Average length of longest neurite. d Mean length of small, medium, and large neurites. Number of animals per group: sham vehicle (veh) n = 5, 
QUIS (veh) n = 5, QUIS (LY) n = 4. Data are represented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar 25 μm.
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results in early (3  days post injury) enhanced neuronal 
growth primarily in small fibers, and these effects can be 
blocked with LY294002 treatment.
LY294002 effect on reducing GSK-3βP expression and 
potent effect on restricting early injury induced growth 
suggests that LY294002 may, in part, mediate its growth 
inhibiting effects through PI3K-GSK-3β signaling.
Short term administration GSK‑3β activator (LY294002) 
prevents the development of at‑level spontaneous 
dysesthesias and reduces DRG outgrowth following QUIS 
spinal cord injury
The excitotoxic QUIS spinal cord injury model reliably 
results in the development of at-level dysesthesia char-
acterized by excessive overgrooming behavior directed 
towards the dermatome associated with the level of 
injury that typically develops 6–12 days post injury [48, 
49]. At-level dysesthesias develop 40–60% of all injured 
animals [48, 50]. This self-directed biting and scratch-
ing behavior results in hair removal and has been sug-
gested to represent at-level sensory disturbances in this 
SCI model [48, 49] (Figure  5a). To assess the effect of 
LY294002 on at-level dysesthesias/overgrooming we 
extended the time course to 14  days survival follow-
ing injury. Animals were randomly assigned the follow-
ing groups: sham vehicle (sham veh; 10% DMSO, n = 9) 
control, QUIS-vehicle (QUIS veh; 10% DMSO, n = 12), 
or QUIS LY294002 (QUIS LY, 2.5  μg/10  μL, n  =  11). 
Five QUIS veh animals developed overgrooming (class 
I, n  =  2; class II, n  =  3). LY294002 treatment initiated 
immediately following QUIS injury and once daily there-
after for three consecutive days significantly reduced the 
incidence of overgrooming behavior from 42% (n = 5/12) 
in QUIS veh animals to 0% (n = 0/11) in QUIS LY294002 
treated animals (p < 0.05) (Figure 5b).
To verify the LY294002 treatment effect on peripheral 
growth, cultured DRG were assessed from each of the 
following groups at the 14  day time point: sham vehi-
cle (sham veh, n  =  9), QUIS veh nongroomers (QUIS-
NG veh, n  =  12), QUIS veh Groomers (QUIS-GR veh, 
n = 5), and QUIS-LY294002 (QUIS LY, n = 11). Consist-
ent with our previous report, cultured DRG from QUIS-
GR-veh (44%, n  =  524/1,184 neurons, p  <  0.0001) and 
QUIS-NG veh (51%, n  =  221/431, p  <  0.001) animals 
showed an increase in the neurons with neurites com-
pared to sham treated controls (34%, n = 144/423) (Fig-
ure  6a, b). QUIS-induced neurite elongation was most 
robust in animals displaying the sensory dysesthesias 
(QUIS-GR veh; 131.2 μm ± 14.2, n = 524) compared to 
sham (58.1 μm ± 9.7, n = 144, p < 0.001), QUIS-NG veh 
(75.0 μm ± 8.7, n = 221, p < 0.001) (Figure 6a, c). QUIS 
animals treated with LY294002 showed significant reduc-
tions in neurite formation (19.7%, n = 332/1,685, p < 0.05) 
and elongation (30.9  μm  ±  2.2, n  =  332, p  <  0.0001) 
compared to the sham-vehicle animals (Figure  6b, c). 
The enhanced DRG growth from QUIS-Groomers was 
evident in small (53.0 μm ± 9.3, n = 159, p < 0.05) and 
large (113.5 μm ± 15.5, n = 236, p < 0.01), compared to 
Figure 5 LY294002 treatment following QUIS-induced spinal injury prevents the development of at-level dysesthesias 14 days after injury. a Photo-
graph of overgrooming lesion from QUIS vehicle treated animal primarily observed on at-level ipsilateral dermatome, class II bilateral groomer.  
b The incidence of overgrooming behavior was reduced from 42% (5/12) in animals treated with DMSO to 0% in animals treated with LY following 
SCI (0/11; p = 0.03).
Page 8 of 15Bareiss et al. Mol Pain  (2015) 11:35 
sham (small, 22.1 μm ± 6.1, n = 35; large 46.1 μm ± 9.5, 
n =  78) (Figure  6d). QUIS induced growth of small and 
large DRG was significantly decreased with LY treatment 
(QUIS LY; small 26.2 μm ± 2.9, n = 62, p < 0.05; large, 
23.0  μm  ±  2.1, n  =  151, p  <  0.001) (Figure  6d). These 
results showed that at-level dysesthesias and enhanced 
Figure 6 At-level QUIS-induced dysesthesias are associated with enhanced neurite outgrowth that is reduced with 3 day intrathecal delivery 
LY294002 (LY) 14 days following injury. a Representative immunofluorescent images of cultured DRG neurons from sham (sham veh, n = 9), QUIS 
nongroomers (QUIS-NG veh, n = 7), QUIS groomers (QUIS-GR veh, n = 5), QUIS LY294002 (QUIS LY, n = 11) taken ipsilateral to the injection site and 
grooming (T12) 14 days post-surgery. b, c DRGs from QUIS nongrooming (QUIS-NG veh) and grooming (QUIS-GR veh) animals show enhanced 
neurite growth initiation, DRG from QUIS-GR veh animals show enhanced neurite elongation compared to sham veh and QUIS-NG veh. Short 
term (3 days) intrathecal delivery of LY294002 (QUIS-LY) significantly decreased the percentage of neurons with neurites and the length of neurites 
following QUIS injury. d DRG growth responses were enhanced in small and large neurons 14 days post injury in QUIS-GR compared to sham veh 
controls. DRGs from QUIS-LY animals showed significant reductions in small and large DRG growth responses (mean ± SEM; *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001).
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DRG growth 14 days following QUIS spinal injury is pre-
vented with early, short term LY294002 treatment.
Discussion
This study demonstrates a role for altered GSK-3β activity 
resulting in enhanced DRG neurite outgrowth following 
excitotoxic spinal injury. Biochemical and immunohis-
tochemical approaches showed that excitotoxic spinal 
lesions resulted in strong (early and persistent) GSK-3β 
inhibition in the spinal cord dorsal horn and adjacent 
DRG neurons. Intrathecal treatment with a PI3K inhibi-
tor (LY294002), a known GSK-3β activator, blunted 
injury induced neurite initiation and elongation. Short 
term intrathecal delivery of LY294002, initiated at the 
time of injury, significantly reduced GSK-3β inhibition in 
the spinal dorsal horn and adjacent DRG and prevented 
the development of at-level dysesthesias. These data sug-
gest that QUIS induced spinal injury results in GSK-3β 
inhibition and peripheral afferent growth that contrib-
utes to the development of at-level neuropathic pain fol-
lowing SCI.
Peripheral growth responses in the development 
of at‑level sensory disturbances
Historically, efforts to understand the development of 
neuropathic pain following SCI have focused on the 
injury epicenter and supraspinal regions [51]. This study 
along with previous results from our lab [6] has shown 
that QUIS spinal injury results in at-level induced dys-
esthesias associated with enhanced DRG growth. These 
finding are supported by Bedi et al. which showed simi-
lar at-level peripheral growth promoting effects along 
with spontaneous activity/hyperexcitability in a contu-
sion model, suggesting that the growth responses were 
not unique to the SCI model [7, 8]. Consistent with these 
reports, we demonstrated that spinal injury induced 
DRG growth was evident early (3  days post-injury) and 
persisted throughout a 14 days survival period. Although 
latent DRG growth (14  day post-injury) was evident in 
small and large fibers, early injury induced growth (3 day 
post-injury) was most prominent in small DRG neurons, 
a finding that is supported by reports showing a temporal 
window of nociceptive sprouting occurring early post-
SCI [8, 14]. It is possible that these growth promoting 
effects in small (C and Aδ) and large (Aβ) fibers contrib-
ute to the intraspinal sprouting and structural plasticity 
in dorsal horn circuitry that may, in part, contribute to 
pain post-SCI [11, 14, 15, 52–56]. These findings along 
with the increased GSK-3βP expression (and expansion 
into deeper layers) in the dorsal horn, provide further 
evidence to support a role for maladaptive structural 
plasticity post-spinal injury. Collectively, the early growth 
of peripheral afferent post-spinal injury suggests that 
these responses may lead to maladaptive plasticity and 
reorganization in the dorsal horn afferents contributing 
to the development of at-level sensory disturbances.
GSK‑3β as a regulator of DRG outgrowth following SCI
These studies provide the first evidence to support a role 
for GSK-3β signaling as a regulator of peripheral affer-
ent plasticity following spinal injury. GSK-3β is well-
established for its role in neuronal morphogenesis via 
regulation of an extensive list protein substrates, such 
as collapsin response proteins [29, 32, 57], APC [20], 
CLASP-associated proteins [58, 59], δ-catenin [28, 30], 
microtubule associated proteins [60–64]. Regulation of 
these cytoskeletal proteins to promote neurite elongation 
is accomplished through fine-tuned control of GSK-3β 
activity [22, 39], were partial inhibition of GSK-3β via 
phosphorylation on Serine-9 leads to neurite elonga-
tion, and strong (inhibition) suppression or activation 
of GSK-3β leads to termination of neurite outgrowth. 
Here we demonstrated that QUIS induced SCI results in 
GSK-3β inhibition (spinal cord dorsal horn and adjacent 
DRG) and robust DRG neurite growth.
We demonstrated that opposing actions directed 
towards GSK-3β activation, using the PI3K inhibi-
tor LY294002, effectively suppressed DRG neurite ini-
tiation and elongation following QUIS induced spinal 
injury. Although LY294002 is a potent inhibitor of PI3K/
Akt pathways that targets GSK-3β activation, its effects 
are not direct; and therefore LY294002 may also acti-
vate Akt/mTOR pathways to restrict neurite outgrowth 
[20, 41, 65]. While LY294002 leads to activation of the 
mTOR pathway in the central nervous system, emerging 
evidence suggests that mTOR signaling does not con-
trol sensory afferent growth providing further evidence 
that PI3K-GSK-3β signaling is critical in mediating post 
injury DRG growth [42]. Our finding that intrathecally 
delivered LY294002 blocked the SCI induced increases 
in GSK-3βP expression also supports that these effects 
are, in part, mediated through PI3K-GSK-3β signaling. 
This is in agreement with studies showing potent effects 
of LY294002 to activate GSK-3β and prevent neurite 
outgrowth [20, 41, 66]. Collectively, these data provide 
morphological evidence for the role of PI3K-GSK-3β 
signaling in SCI induced primary afferent growth.
GSK‑3β is a convergent signaling target to pro‑nociceptive 
factors released in response to spinal injury
In support of GSK-3β as a mediator of aberrant affer-
ent growth and sensory disturbances, GSK-3β is a con-
vergent signaling effector of established pro-nociceptive 
signals including nerve growth factor (NGF), PI3K, and 
Wnts [26, 34, 35, 43, 45, 46, 67, 68]. Numerous studies 
have shown that peripheral and central nervous system 
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injury results in upregulation of neurotrophins and Wnts 
that may inhibit GSK-3β and contribute the anatomi-
cal remodeling in spinal dorsal horn and DRG to induce 
neuropathic pain [34, 67, 69–71]. Furthermore, efforts 
to block the effects of NGF, Wnts, and PI3K are effec-
tive at preventing the development of neuropathic pain 
and autonomic dysreflexia [11, 34, 36, 45, 46, 69, 72]. 
Substantial evidence suggests that these extracellular sig-
nals released following injury converge to phosphoryl-
ate/inactivate GSK-3β to cause neurite elongation [20, 
26, 73–77]. Interestingly, studies have demonstrated that 
activation of PI3K is required for NGF-induced neurite 
elongation, and therefore our finding that demonstrated 
alterations PI3K-GSK-3β signaling following QUIS spinal 
cord injury provides an intracellular link that underlies 
these structural responses following injury [20, 78, 79].
Altered GSK‑3β activity in the spinal dorsal horn and DRG 
in neuropathic pain
Recent studies have provided evidence for the role of 
altered GSK-3β activity in development of neuropathic 
pain, showing that GSK-3βP (inactive) is distributed in 
the spinal cord dorsal horn axons where it is positioned 
to influence sensory growth and synaptic plasticity [66, 
80]. Although the temporal relationship between GSK-3β 
activities and pain following nervous system injury are 
largely unexplored, Weng et  al. recently showed that 
peripheral nerve injury resulted in early increases in 
GSK-3βP in the spinal cord dorsal horn [80]. This find-
ing is consistent with our data (Figure 1, 3) showing early 
and persistent inhibition of GSK-3β in the DRG and 
spinal cord dorsal horn following excitotoxic SCI (evi-
dent at 3 and 14  days post-injury). In support of these 
findings, peripheral nerve injury induces early activa-
tion PI3K-Akt in spinal dorsal horn and DRG neurons, 
an established upstream signal to inhibit GSK-3β activ-
ity [36]. Furthermore, activation of PI3K/Akt following 
peripheral nervous system injury are strongly expressed 
in small, nociceptive neurons that have an established 
role in early central sensitization which contributes to the 
development of neuropathic pain [36, 43, 81]. Interest-
ingly, reports have shown that activation of PI3K-GSK-3β 
following injury are transient, occurring within 3  days 
post-injury [36, 80]. Our reported inhibition of GSK-3β 
that extended throughout 14  days post-injury may be 
attributed to differences between peripheral vs. central 
injury, as well as the progressive nature created by the 
QUIS-excitotoxic spinal injury [48]. Additional evidence 
for the role of GSK-3β in SCI pain is supported by the 
finding that NGF, an inhibitor of GSK-3β with a pivotal 
role in primary afferent sprouting, is increased in the spi-
nal cord and DRG following SCI [20, 25, 35, 67]. Further 
studies are needed to examine how different SCI models 
impact GSK-3β, activity as well as the time course for 
these changes. Nonetheless, our studies provide the first 
link by which spinal injury can directly impact GSK-3β 
activity in a manner that would lead to sensory afferent 
outgrowth/sprouting and sensory dysesthesias.
Although GSK-3β plays a pivotal role in regulating 
structural neuronal plasticity [20, 22, 27, 79], GSK-3β 
also regulates other cellular functions including cell sur-
vival pathways, and more recent reports demonstrating 
a role in pro-inflammatory processes [16, 19, 80, 82]. As 
such, activation of GSK-3β may contribute to enhanced 
secondary damage and neuronal apoptosis associated 
with SCI [83]. To ensure that our observed differences 
with LY294002 treatment were not related to enhanced 
neuronal death, cell quantification of the proportion of 
different neuronal types and cell densities showed that 
the overall number and distribution of cell size of our 
neuronal cultures from LY294002 treated were compara-
ble to those from sham-operated and QUIS-injected ani-
mals (data not shown) [6, 8], suggesting that our reported 
differences were not related to enhanced neuronal death 
from drug treatment. Furthermore, there are emerging 
reports showing that application of GSK-3β inhibitors 
may prevent the development of pain or reduce sec-
ondary damage following peripheral or central nervous 
system injury potentially through reduced inflamma-
tory responses [83–85]. Several of these studies employ 
preemptive treatments [80, 84, 85], strategies that may 
have limited efficacy for the treatment of neuropathic 
pain following SCI resulting from unexpected trauma or 
ischemia. Other studies use systemic (intraperitoneal) 
drug delivery which lacks targeted delivery and may, 
therefore, have off target consequences that contribute 
to the differences observed with activation vs. inhibi-
tory action of GSK-3β to prevent neuropathic pain [83, 
86]. It is plausible that the reported protective effects of 
both GSK-3β inhibition and activation may be related to 
different mechanism of action based on mode of deliv-
ery (intraperitoneal vs. intrathecal), pain model (acute 
vs. neuropathic), and the timing of drug administration 
(preemptive vs. acute short term). Our study provides 
evidence into the temporal and spatial alterations of 
GSK-3β activity following spinal injury; to establish that 
early intratehecal delivery of LY294002 (a known GSK-3β 
activator) was successful at preventing the development 
of at-level dysesthesias.
PI3K‑GSK‑3β signaling in sensory and motor neurite 
outgrowth
Molecular signaling pathways, such as PI3K-GSK-3β 
that control axonal growth are shared between sen-
sory and motor fibers [20, 25], making therapeutics that 
regulate structural plasticity challenging. The growth 
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promoting effects of GSK-3β has made inhibition of 
this enzyme an appealing target to promote motor fiber 
regeneration following SCI. This has resulted in clini-
cal and experimental studies using GSK-3β inhibitors to 
promote axonal regeneration following SCI [25, 87, 88]. 
Recent studies now raise the possibility that GSK-3β 
inhibition will not effectively promote long-distance 
axonal growth and may further restrict spinal cord 
regeneration [32, 87, 89]. Here we also demonstrated 
that excitotoxic SCI resulted in GSK-3β inhibition, and 
further suppression with GSK-3β inhibitors may pre-
vent sensory outgrowth and possibly the desired axonal 
motor fiber regeneration.
Understanding of the temporal and spatial nature of 
the growth promoting effects are of particular impor-
tance following SCI, where efforts to control struc-
tural neuroplasticity and regeneration are opposing, 
to promote motor fiber regeneration and yet limit sen-
sory sprouting and growth that contributes to pain 
syndromes post-injury [52, 53]. Our finding that DRG 
growth responses contribute to at-level pain syndromes 
is significant as therapeutics to prevent maladaptive 
growth responses work towards targeted approaches to 
improve clinical efficacy [52, 53, 90, 91]. Our short term 
intrathecal delivery of LY294002 was effective at block-
ing peripheral outgrowth and at-level dysesthesias, how-
ever future studies investigating targeted delivery to the 
periphery (DRG) are needed to prevent pain and allow 
for motor fiber recovery post-SCI. Furthermore, our 
previous report and other studies have demonstrated 
that SCI results in primary afferent growth and sensiti-
zation in segments remote from the site of injury [6, 8, 
14, 15, 92]. Studies are underway to investigate the effect 
of injury induced growth on distant segments to deter-
mine if activation of GSK-3β can prevent and reverse the 
development of below-level hyperalgesia and allodynia 
following SCI [48]. This study identified a therapeutic 
window specific to target inhibition of at-level sensory 
growth. Future studies using traumatic SCI models to 
incorporate the motor complications and determine the 
appropriate therapeutic timeline to maximize motor 
recovery while minimizing the risk for the development 
of pain are needed.
Conclusion
In summary, these studies identify PI3K-GSK-3β sign-
aling as a mechanism controlling maladaptive primary 
afferent growth in the development of at-level excito-
toxic SCI induced dysesthesias. We have shown that 
acute short term (3 days) treatment with a GSK-3β acti-
vator, LY294002, is sufficient to prevent the develop-
ment of at-level sensory dysesthesias and reverse injury 
induced DRG growth responses. These data support that 
targeting GSK-3β may be therapeutic to prevent mala-
daptive growth and at-level pain following SCI.
Methods
Animals and excitotoxic QUIS induced spinal cord (dorsal 
horn) injury
All experimental procedures were approved by the Insti-
tutional Animal Care and Use Committee at East Caro-
lina University. The surgical intramedullary injection 
technique was similar to previously described methods 
[48, 93]. Briefly, male Long Evans rats (175–200 g) were 
anesthetized, a posterior midline incision was made 
along the thoracolumbar junction. A laminectomy was 
completed at approximately T11-L1 and dura was incised 
longitudinally and retracted. A glass micropipette with 
5–10  μm tip diameter was attached to a 10  μm Ham-
ilton syringe for injections. The syringe was mounted 
on a microinjector (Kopf 5000) and micromanipula-
tor. Intramedullay injections of 125 mM quisqualic acid 
(QUIS, Sigma, St. Louis, MO, USA) were made in the 
dorsal root entry zone of the spinal cord (between the 
midline vessel and lateral aspect) at a depth of 1,000 μm 
below the surface of the cord. Unilateral injections were 
made in a single segment at the T12 spinal level. Ani-
mals received either 1.2 μL of phosphate buffered saline 
(PBS, sham) or QUIS over a 60-s time interval (3 tracks 
of 0.4 μL separated by 0.3 μm parallel to the long axis of 
the cord). In an initial set of experiments, animals under-
went QUIS-injection or sham-injection and were allowed 
to survive for 14 days following surgery without cannula-
tion or drug delivery (sham, n = 5; QUIS, n = 6).
Surgical procedures for intrathecal drug delivery
For animals receiving intrathecal injections, immediately 
following QUIS or PBS spinal injections, a polyethylene 
catheter (PE-10 tubing) was inserted under the open dura 
into the intrathecal space immediately caudal to the site 
of injection. The catheter was secured in place by sutur-
ing to spinal muscles along the length of the surgical inci-
sion. The rostral end of the catheter was tunneled under 
the skin, externalized at the back of the neck and secured 
with sutures and skin adhesive (VetBond). Spinal muscles 
were closed around the catheter, and the incisions were 
closed with staples. Animals from each group (QUIS-
injected vs. sham-injected) were randomized to receive 
intrathecal LY294002 (PI3K inhibitor, 0.5  µg in 10  µL 
of vehicle) or an equal volume of vehicle (10% DMSO). 
Drugs were delivered once daily for 3 days, and animals 
were euthanized at 3 or 14  days following surgery. The 
number of animals for each time point were as follows: 
3 day Sham vehicle (veh) n = 5, QUIS (veh) n = 5, QUIS 
(LY) n = 4; QUIS (LY) n = 3; 14 day Sham (veh) n = 9, 
QUIS (veh) n = 12, QUIS (LY) n = 11.
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DRG cultures and morphological analysis
Culturing of DRG were performed as previously described 
[94]. At the end of the survival period (3 or 14 days), ani-
mals were deeply anesthetized with isoflurane while the 
thoracolumbar vertebral column was removed. Two 
DRG were collected ipsilateral to the injection and side of 
grooming (T11-T12) in QUIS and sham (saline-injected) 
animals and immediately placed in Hibernate A (Brain-
Bits, Springfield, IL, USA) with 10% horse serum and 
100 microgram/μL penicillin, 100  μg/μL streptomycin. 
DRG were washed in plating media containing Pen/Strep, 
disassociated enzymatically via use of (2  μg/mL) colla-
genase (Sigma, St. Louis, MO, USA) and 0.25% trypsin/
EDTA (Invitrogen, Grand Island, NY, USA) and mechani-
cally via microsnipping and trituration through a pol-
ished Pasteur pipette. Cells were plated at low density 
onto glass coverslips in 24-well plate (coated with 100 μg/
μL of poly-l-lysine and 10 μg/μL laminin), incubated at 
37°C in plating medium containing DMEM/F12 contain-
ing 10% fetal bovine serum, 10% horse serum, 2 mM glu-
tamine, 100  μg/μL penicillin, 100  μg/μL streptomycin. 
After 24 h cells were fixed with 4% paraformaldehyde and 
washed with PBS. Cells were permeabilized with 0.2% 
Triton, blocked with 10% PBS, and stained with rabbit 
anti-tubulin III (Sigma, St. Louis, MO, USA, 1:75) anti-
body conjugated to anti-rabbit secondary cy3 (Jackson 
ImmunoResearch, 1:300). Coverslips were mounted onto 
slides using ProLong Gold with DAPI (Invitrogen), used 
to visualize the cell nucleus. Images were captured at 40× 
magnification with the Leica DM4000 microscope using 
a Q imaging Retiga 2000R camera. Image-Pro Express 6.3 
software was used for neuronal measurements. Soma size 
was measured and cells were categorized based on the fol-
lowing criteria: small <30.4 μm, medium 30.5 - 45.4 μm, 
and large >45.0 μm. Neurons with neurites above 10 μm 
were measured for the length of the longest neurite. The 
total number of neurons, total number of neurons with 
neurites (above 10  μm), and average maximum neurite 
length were calculated for each condition. Measurements 
for longest neurite were traced from the soma to the most 
distal tip of the neurite. DRG from the respective groups 
(3 days: sham veh, QUIS veh, QUIS LY; 14 days sham veh, 
QUIS-NG veh, QUIS-GR veh, and QUIS-LY) were pooled 
a minimum of five coverslips and more 400 neurons were 
counted for each condition. An equal number of cells 
were plated for each condition, cell densities 1  day after 
dissociation was 80  ±  17 cells/coverslip. Experiments 
were performed by an investigator that was blinded to the 
conditions.
Western blotting
Spinal cord from T12 (at-level injection) and adjacent 
DRG from saline (sham) (n  =  3) and QUIS-injected 
(n =  3) animals (14  day survival period) were homoge-
nized using RIPA buffer (150 mM NaCl, 10 mM HEPES 
pH 7.3, 2 mM EDTA, 0.2% SDS, 0.5% sodium deoxycho-
late, 1% Triton X-100) with protease inhibitors (Roche 
Complete Protease Inhibitor, Indianapolis, IN, USA). 
Samples were centrifuged at 14,000  g, supernatant was 
collected and protein concentration was determined 
by Pierce BCA assay (Thermo Scientific). Samples were 
boiled for 5  min and equal amounts of protein were 
loaded and run on SDS-PAGE gels, transferred to nitro-
cellose membranes, and immunoblotted for total anti-
mouse GSK-3β and anti-rabbit phospho-Ser9-GSK-3β 
(GSK-3βP) (Cell Signaling Technology, Beverly, MA; 
1:1,000). Bound antibodies were detected with horserad-
ish peroxidase-conjugated anti-rabbit and anti-mouse 
immunoglobulin G (Promega, Madison, WI, USA; 
1:2,500). Western-blotted protein bands were quanti-
fied with UN-SCAN-IT software (Silk Scientific, Inc. 
Orem, UT, USA). Proteins levels reported in figures were 
obtained as a ratio between GSK-3βP and total GSK-3β.
Immunohistochemistry
Spinal column and dorsal root ganglia were removed 
and placed in 4% paraformaldehyde for 24  h and trans-
ferred 30% sucrose in phosphate buffered saline (PBS). 
Spinal cord (L1 spinal level, 25 μm) and DRG (L1 ipsi-
lateral lesion, 16  µm) were cryosectioned using a Leica 
2400 sledge microtome. Tissue sections were blocked (3% 
donkey serum, 1% BSA, 0.3% Triton X-100 in PBS) for 
1 h at room temperature. Tissue was then incubated with 
primary antibody (GSK3-βP, 1:50, Cell Signaling Technol-
ogy) and placed in a humidity chamber overnight at 4 °C. 
Double immunolabeling of DRG sections were incubated 
with GSK-3βP and nociceptive markers: Isolectin-B4 
20 μg/ml; (Sigma, St. Louis, MO, USA), calcitonin gene 
related peptide (CGRP; 1:150 abcam, Cambridge, MA, 
USA), and myelinated A-fiber marker neurofilament-200 
(NF200; 1:200 abcam, Cambridge, MA, USA). Tissue 
was rinsed with PBS and incubated with secondary anti-
body for 1 h at room temperature (rabbit cy3, 1:300 and 
for double labeling combined with mouse-FITC (1:100) 
(Jackson ImmunoResearch, West Grove, PA, USA). Sec-
tions were rinsed with PBS 3 times and coversliped with 
VectaShield with DAPI (Burlingame, CA, USA).
Immunohistochemistry image analysis
Spinal cord dorsal horn (L1) and DRG (L1) images 
were captured <24  h after coverslipping using a Leica 
DM4000 microscope, images were acquired using a 
Retiga 2000R camera (Q imaging) on a at 10× (SC) and 
40× (DRG) magnification. For each animal, every third 
or fourth of consecutive sections. (4 DRG and 6 dorsal 
horn images) were captured at the same magnification, 
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lens aperture and exposure time using Image Pro 
Express software (Media Cybernetics, Rockville, MD, 
USA). Image analysis was performed using ImageJ 
(NIH). Due to changes in laminae structure following 
QUIS injection, we assessed changes in immunofluo-
rescence density using segments just caudal to the site 
of injury (L1) using an area of interest (AOI) method 
previously described [95]. For dorsal horn analysis, the 
AOI was placed in the most central portion horizontally 
with the top corners of the box at the most superficial 
edge of the lamina. Background density threshold was 
established for each image using the standardized box 
(AOI). Immunofluorescence for dorsal horn laminae 
were measured and subtracted from background densi-
ties. An average optical density was obtained for each 
animal and a mean value for each group was reported. 
A percent change from sham to QUIS-injected animal 
was determined in order to show differences in the two 
conditions. All histological analysis was performed by a 
blinded investigator.
Excessive grooming behavior
Animals were assessed once daily starting on day 6 post-
injection for the presence of overgrooming (at-level 
spontaneous dysesthesia) directed towards the der-
matome associated with the level of injury [48, 96]. This 
behavior is characterized by self-directed biting/scratch-
ing that results in hair removal and progressive damage 
to the skin and has been suggested to represent at-level 
spontaneous sensory disturbances in this model [48]. The 
excessive grooming behavior was categorized as class I–
IV as previously described [97]: class 1—hair removal 
over portions of a dermatome, class II—extensive hair 
removal with signs of damage to the superficial skin lay-
ers, class III—hair removal and damage to dermal layers 
of the skin, class IV—damage to subcutaneous tissue.
Statistical analysis
Statistical analyses were performed using GraphPad 
Prism 5.04 software (San Diego, CA, USA). All data are 
reported as mean  ±  standard error (SEM) through-
out, with statistical significance set at p < 0.05. One way 
ANOVA followed by Bonferron’t post hoc comparison or 
paired t tests when applicable were used to identify dif-
ferences between group means. Non parametric values 
were analyzed with Pearson Chi square test.
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